Abstract
Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC.
Keywords:
DAAs; HCV; Occult B hepatitis; Reactivation.
MeSH terms
-
Aged
-
Anti-Inflammatory Agents / administration & dosage
-
Antiviral Agents / therapeutic use*
-
Cryoglobulinemia / complications
-
Cryoglobulinemia / drug therapy
-
DNA, Viral / blood
-
Female
-
Guanine / analogs & derivatives
-
Guanine / therapeutic use
-
Hepatitis B / complications
-
Hepatitis B / drug therapy*
-
Hepatitis B Antibodies / blood
-
Hepatitis B Surface Antigens / blood
-
Hepatitis B virus / genetics
-
Hepatitis C / complications*
-
Hepatitis C / drug therapy
-
Humans
-
Immunologic Factors / therapeutic use
-
Prednisolone / administration & dosage
-
Recurrence
-
Ribavirin / therapeutic use*
-
Rituximab / therapeutic use
-
Sofosbuvir / therapeutic use*
-
Viral Load
Substances
-
Anti-Inflammatory Agents
-
Antiviral Agents
-
DNA, Viral
-
Hepatitis B Antibodies
-
Hepatitis B Surface Antigens
-
Immunologic Factors
-
Ribavirin
-
Rituximab
-
entecavir
-
Guanine
-
Prednisolone
-
Sofosbuvir